[Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].

Abstract	The basic conditions in the management of exudative age-related macular degeneration have changed considerably since the last statement of the German professional associations in 2006. While Pegaptanib was approved in Germany already in 2006 Ranibizumab was approved for the treatment of exudative macular degeneration in Germany in February 2007. More over the quality assurance regulations for the photodynamic treatment of choroidal neovascularizations with Verteporfin were modified including the treatment of occult lesions and implementing a simplified classification of extra- and subfoveal lesions. Consequently modification of the recommendations for the non-surgical treatment of exudative age-related macular degeneration appeared inevitable.
Authors
Journal	Klinische Monatsblatter fur Augenheilkunde (Klin Monbl Augenheilkd) Vol. 224 Issue 7 Pg. 559-66 (Jul 2007) ISSN: 0023-2165 [Print] Germany
Vernacular Title	Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration.
PMID	17657689 (Publication Type: Consensus Development Conference, Journal Article, Practice Guideline)
Chemical References	Angiogenesis Inhibitors Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Aptamers, Nucleotide Porphyrins Pregnadienediols Vascular Endothelial Growth Factor A Verteporfin pegaptanib Bevacizumab Triamcinolone Acetonide anecortave acetate Ranibizumab
Topics	Angiogenesis Inhibitors (adverse effects, therapeutic use) Antibodies, Monoclonal (adverse effects, therapeutic use) Antibodies, Monoclonal, Humanized Aptamers, Nucleotide (adverse effects, therapeutic use) Bevacizumab Choroidal Neovascularization (drug therapy) Drug Therapy, Combination Evidence-Based Medicine Humans Macular Degeneration (drug therapy) Ophthalmology Photochemotherapy Porphyrins (therapeutic use) Pregnadienediols (adverse effects, therapeutic use) Ranibizumab Societies, Medical Triamcinolone Acetonide (adverse effects, therapeutic use) Vascular Endothelial Growth Factor A (antagonists & inhibitors) Verteporfin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!